Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma

Annals of Hematology

Volumn 85, Issue 9, 2006, Pages 597-603

  Espinosa, Iñigo ^a   Briones, Javier ^a   Bordes, Ramon ^a   Brunet, Salut ^a   Martino, Rodrigo ^a   Sureda, Ana ^a   Prat, Jaime ^a   Sierra, Jorge ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

B cells; Immunohistochemistry; Non Hodgkin's lymphoma; PKC beta 2 protein; Prognostic factor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN KINASE C BETA; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL MEMBRANE; CHILD; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROTEIN KINASE C; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 33747825439     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0144-y     Document Type: Article

References (21)

1. Coiffier B (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13:325-334
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511
4. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346:1937-1947
5. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:9991-9996
6. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282
7. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS et al (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74
8. Spitaler M, Cantrell DA (2004) Protein kinase C and beyond. Nat Immunol 5:785-790
9. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA, Kato RM, Kang S, Patrone L, Wall R et al (2002) PKC-beta controls IkappaB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2:780-786
10. Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A (2002) Protein kinase C beta controls nuclear factor kappa B activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 195:1647-1652
11. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delson G, De Wolf-Peeters C, Falini B, Gatter KC et al (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361-1392
12. Colomo L, López-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E (2003) Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101:78-84
13. Kaplan GL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
14. 2/E in log-rank test for survival date or tumour incidence date. Biometrics 29:759-784
15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253
16. Cox DR (1972) Regression models and life tables. J R Stat Assoc 34:187-220
17. Saez AI, Saez AJ, Artiga MJ, Perez-Rosado A, Camacho FI, Diez A, García JF, Fraga M, Bosch R, Rodriguez-Pinilla SM et al (2004) Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 164:613-622
18. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT, Pan Z, Smith LM, Lynch JC, Bociek RG et al (2005) Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 18(10):1377-1384 (May 13)
19. Guo B, Su TT, Rawlings DJ (2004) Protein kinase C family functions in B-cell activation. Curr Opin Immunol 16:367-373
20. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood 101:4279-4284
21. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1507-1517